Wolters Kluwer Health (EURONEXT: WKL) announced on Wednesday that it has launched AI Article Summary on its Ovid platform, enabling researchers to quickly extract insights from peer-reviewed literature. Currently in Beta across selected LWW proprietary journals, the tool uses generative artificial intelligence to deliver concise, trustworthy summaries, streamlining information gathering for healthcare professionals, researchers and students.
AI Article Summary helps users identify key points from lengthy research papers, addressing the challenge posed by the growing volume of daily published studies. The feature supports rapid knowledge sharing among colleagues and allows clinicians and researchers to stay current with the latest evidence. Summaries are structured consistently across journals, providing practical, actionable information that aligns with clinical decision-making.
Designed with research workflows in mind, Ovid's AI summarisation highlights critical findings and methodological insights without requiring users to leave the platform. Specialized prompt engineering ensures clinically and scientifically relevant information is extracted efficiently and reliably.
Wolters Kluwer is a global provider of information, software solutions, and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance; and ESG. The group reported 2024 revenues of EUR5.9bn, serving customers in over 180 countries with operations in more than 40 nations and a workforce of approximately 21,600. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA